Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Benitec Biopharma (BNTC) Receivables - Other (2019 - 2020)

Benitec Biopharma has reported Receivables - Other over the past 2 years, most recently at $21000.0 for Q4 2020.

  • Quarterly results put Receivables - Other at $21000.0 for Q4 2020, changed N/A from a year ago — trailing twelve months through Dec 2020 was $21000.0 (changed N/A YoY), and the annual figure for FY2020 was $59000.0, down 96.89%.
  • Receivables - Other reached $21000.0 in Q4 2020 per BNTC's latest filing, down from $59000.0 in the prior quarter.
  • Across five years, Receivables - Other topped out at $1.9 million in Q2 2019 and bottomed at $21000.0 in Q4 2020.